Evidence map›Paper›PMID 29340905›Full record

ArticleMedical oncology (Northwood, London, England)2018

Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.

Lidija Todorović, Boban Stanojević, Vesna Mandušić, Nina Petrović, Vladan Živaljević, Ivan Paunović, Aleksandar Diklić, Vladimir Saenko, Shunichi Yamashita

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Lidija TodorovićLaboratory for Radiobiology and Molecular Genetics, "Vinča" Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia. lidijat@vinca.rs.ORCID http://orcid.org/0000-0003-0672-0693
Boban StanojevićLaboratory for Radiobiology and Molecular Genetics, "Vinča" Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.
Vesna MandušićLaboratory for Radiobiology and Molecular Genetics, "Vinča" Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.
Nina PetrovićLaboratory for Radiobiology and Molecular Genetics, "Vinča" Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.
Vladan ŽivaljevićCenter for Endocrine Surgery, Clinical Center of Serbia, Belgrade, Serbia.
Ivan PaunovićCenter for Endocrine Surgery, Clinical Center of Serbia, Belgrade, Serbia.
Aleksandar DiklićCenter for Endocrine Surgery, Clinical Center of Serbia, Belgrade, Serbia.
Vladimir SaenkoAtomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Shunichi YamashitaAtomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
University of Belgrade · RSNagasaki University · JP

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (RS) ON173049
6 · The paper itself

Abstract

A growing body of evidence suggests a role of the von Hippel-Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up- or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069-0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109-19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = - 0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified.

Indexed as

Gene Expression Regulation, NeoplasticAdenocarcinoma, FollicularAdolescentAdultAgedBiomarkers, TumorCarcinoma, PapillaryCase-Control StudiesFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMicroRNAsMiddle AgedNeoplasm InvasivenessBiomarkers, TumorMicroRNAsMIRN92 microRNA, humanVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinAggressive featuresExpressionmiR-92aPTCThyroid cancerVHL

Identifiers

PMID29340905
OpenAlexW2783088221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.